金黄色葡萄球菌菌血症早期口服抗生素转换:金黄色葡萄球菌网络适应性平台(SNAP)试验早期口服转换方案
SNAP试验的早期口服转换(EOS)域评估临床稳定的金黄色葡萄球菌菌血症(SAB)患者早期转换为口服抗生素与继续静脉治疗的对比,主要终点为90天全因死亡率。住院SAB患者在平台第7±2天(无并发症)和第14±2天(有并发症)评估随机化资格。截至2023年8月,21%的SNAP参与者被随机分配到EOS域,共264名参与者分布于77个中心,目标招募至少1000名参与者。
要点
- SNAP试验EOS域评估临床稳定SAB患者早期口服转换与继续静脉治疗,主要终点为90天全因死亡率。
- 无并发症SAB在平台第7±2天评估,有并发症SAB在第14±2天评估随机化资格。
- 截至2023年8月,264名参与者分布于77个中心被随机分配到EOS域,目标至少1000名。
核心结论
- SNAP试验EOS域将评估临床稳定SAB患者早期转换为口服抗生素与继续静脉治疗的对比,主要终点为90天全因死亡率。
研究设计与样本
- SNAP试验的早期口服转换(EOS)域,将临床稳定的SAB患者随机分配至早期口服转换(干预)或继续静脉治疗(当前标准治疗)。
- 住院SAB患者在平台第7±2天(无并发症SAB)和第14±2天(有并发症SAB)评估随机化资格。
主要发现
- 截至2023年8月,21%的SNAP参与者被随机分配到EOS域,共264名参与者分布于77个中心。
- EOS域的目标是招募至少1000名参与者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus bloodstream infection (bacteremia) is traditionally treated with at least 2 weeks of intravenous (IV) antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia (SAB) with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients. PROTOCOL: The early oral switch (EOS) domain of the S. aureus Network Adaptive Platform (SNAP) trial will assess early switch to oral antibiotics compared with continued IV treatment in clinically stable patients with SAB. The primary endpoint is 90-day all-cause mortality. Hospitalised SAB patients are assessed at platform day 7 ±2 (uncomplicated SAB) and day 14 ±2 (complicated SAB) to determine their eligibility for randomization to EOS (intervention) or continued IV treatment (current standard of care). DISCUSSION: Recruitment is occurring in the EOS domain of the SNAP trial. As of August 2023, 21% of all SNAP participants had been randomized to the EOS domain, a total of 264 participants across 77 centers, with an aim to recruit at least 1000 participants. We describe challenges and facilitators to enrolment in this domain to aid those planning similar trials.
引用
- de Kretser D, Mora J, Bloomfield M, et al. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2024. PMID: 37921609. doi:10.1093/cid/ciad666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。